
Abstract: Beta-Amino alcohols, as pivotal frameworks in organic and medicinal chemistry, play a prominent role in drug design and development. This comprehensive review evaluates the therapeutic potential of β-amino alcohols, highlighting their significance in the management of a broad spectrum of human pathologies, including cancer, bacterial infections, malaria, and viral diseases. Furthermore, the efficacy of these molecules in cardiovascular, respiratory, and ocular disorders is assessed. Alongside their therapeutic applications, the epoxide ring-opening process, the primary and most established synthetic pathway for constructing β-amino alcohol cores, is critically discussed and integrated with structure activity relationship (SAR) insights to demonstrate how specific chemical modifications dictate pharmacological potency. The consolidated findings reveal that β-amino alcohols exert their therapeutic effects through diverse molecular mechanisms. These pathways encompass the suppression of malignant cell proliferation, potent bactericidal activity against resistant Staphylococcus aureus strains, inhibition of Plasmodium species in malaria, targeting the main protease (Mpro) of SARS-CoV-2 for COVID-19 therapeutics, and functioning as dual-binding cholinesterase inhibitors for Alzheimer's disease management. Additionally, these derivatives have been reported to modulate adrenergic receptors, highlighting their potential relevance to cardiovascular, respiratory, and ocular therapeutic research, including conditions such as hypertension, asthma, and glaucoma. Overall, this review provides an up-to-date analysis of β-amino alcohol-based therapeutic applications and offers a new perspective on the potential role of these compounds in modern medicinal chemistry, which may contribute to the rational design of novel drug candidates.
The published article [1] requires a correction to the institutional affiliation of the author Talha Bin Emran. The affiliation with Brown University, identified as “Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI 02912, USA,” has been removed from the affiliations listed for Talha Bin Emran. His correct affiliation for this article is “Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.” This correction is limited to the author affiliation information and does not affect the scientific content, results, interpretation, or conclusions of the published article. The article record has been amended accordingly. The specific correction is provided below: Original text: Md. Lutfor Rahaman1, Md. Atiqur Rahman1, Md. Mohin Hasnain1, Mohammad Amran1, Talha Bin Emran2,3, Md Ashikur Rahaman Khan1, Md. Abdul Majed Patwary4, Mohsin Kazi5,* and Mohammed Mahbubul Matin1,* 1Bioorganic and Medicinal Chemistry Laboratory, Department of Chemistry, Faculty of Science, University of Chittagong, Chittagong, 4331, Bangladesh; 2Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI 02912, USA; 3Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh; 4Department of Chemistry, Comilla University, Cumilla, 3506, Bangladesh; 5Department of Pharmaceutics, College of Pharmacy, PO BOX 2457, King Saud University, Riyadh, 11451, Saudi Arabia. Corrected text: Md. Lutfor Rahaman1, Md. Atiqur Rahman1, Md. Mohin Hasnain1, Mohammad Amran1, Talha Bin Emran2, Md Ashikur Rahaman Khan1, Md. Abdul Majed Patwary3, Mohsin Kazi4,* and Mohammed Mahbubul Matin1,* 1Bioorganic and Medicinal Chemistry Laboratory, Department of Chemistry, Faculty of Science, University of Chittagong, Chittagong, 4331, Bangladesh; 2Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh; 3Department of Chemistry, Comilla University, Cumilla, 3506, Bangladesh; 4Department of Pharmaceutics, College of Pharmacy, PO BOX 2457, King Saud University, Riyadh, 11451, Saudi Arabia The original article has been updated accordingly. This corrigendum is published to ensure transparency and accuracy in the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/140819 The authors regret these errors and apologise for any inconvenience they may have caused.
The above article has been retracted by the Publisher and the Editor-in-Chief of Medicinal Chemistry following concerns regarding ethical sourcing and provenance of the human organs or tissues associated with the transplantation research reported in the article. These concerns were raised in the published literature and relate to compliance with internationally accepted ethical standards governing the sourcing and use of organs for transplantation research. The authors were contacted on multiple occasions and were requested to provide clarification and supporting information regarding the ethical provenance of the organs or tissues and the conduct of the study. The authors did not respond to these requests. The authors' institution was subsequently contacted and requested to investigate the matter; however, no response or investigation outcome was received. In the absence of sufficient information or institutional verification to establish that the study complied with applicable ethical standards, the Editor and Publisher are unable to confirm the ethical provenance of the material underlying the reported research. The article is therefore retracted from the scientific record. The original article will remain available in accordance with the journal’s archival policies and will be clearly identified as retracted. The Publisher and Editor-in-Chief regret any inconvenience this action may cause to readers. The Bentham Editorial Policy on Article Retraction is available on the Bentham Science website.
Introduction: Fungal infections continue to pose significant health risks because of two factors, which include drug resistance and the restricted availability of treatment options. Molecular hybridization has been an effective method for developing new drugs with improved therapeutic effects. Fused heterocyclic systems provide researchers with useful frameworks for synthesizing compounds that more effectively engage biological targets. The pyrazole and pyrazolo[ 4,5-b]pyridine derivatives have attracted significant scientific interest due to their multiple biological functions and their ability to be modified in various ways. Methods: The target compounds were prepared through cyclization of naphthalene hydrazide 1 with 2-cyano-N-aryl-acetamide 2a-d to give the key 5-amino-pyrazoles 3a-d. These compounds were then converted into pyrazolo[4,5-b]pyridine derivatives (5a, 5b, 5d, 7a-c) using various chemical routes. Spectroscopic methods (FT-IR, ¹H NMR, and ¹³C NMR) were used for structural identification. An ADMET analysis was conducted to assess the drug likeness and pharmacokinetics of each compound. Finally, the selected compounds were evaluated for antifungal activity against Candida albicans by assessing their ability to inhibit biofilm formation and filamentation. SEM and gene expression studies were conducted to investigate the mechanisms of action, while molecular docking analysis was performed to identify binding interactions with biofilm-associated proteins. Results: Compound 5a showed the highest inhibitory activity (IC50 = 16 μg/mL), with high biofilm inhibition (69%) and filamentation suppression compared to Fluconazole (IC50 = 8 μg/mL, 76.7%). SEM and gene expression data confirmed disruption of the biofilm matrix and the suppression of virulence-related genes. Docking analysis also provided evidence of high-affinity binding to several biofilm-associated proteins. Discussion: The significant biological activity of compound 5a can be explained by the chloro group present on the pyrazolo[4,5-b]pyridine system. On the other hand, compound 7a, despite containing similar groups, exhibited low activity, possibly due to bulky substituents that cause steric hindrance, preventing its interaction with the target molecules involved in fungal virulence. Thus, both biological and molecular docking studies confirm the suitability of compound 5a for use as an antifungal drug. Conclusion: This research has shown that the synthesized pyrazolo[4,5-b]pyridine derivatives showed high antifungal activity. Specifically, compound 5a has been identified as a lead candidate due to its high capacity to disrupt biofilm formation, suppress virulence factor production, and exhibit strong binding affinity for these proteins, thereby making it suitable for the development of future antifungal drugs.
Introduction/Objective: Breast cancer is a major global health issue. A new series of thiazolidinedione-benzimidazole hybrid derivatives (TBZ1–15) was developed and tested for anticancer properties against the MCF-7 breast cancer cell line using the MTT assay. Among these compounds, TBZ-13 showed the greatest cytotoxicity, with an IC₂⁽ of 35 μM. Method: To further elucidate its mechanism of action, TBZ-13 was subjected to multiple in vitro assays, including colony formation, Hoechst staining, reactive oxygen species (ROS) generation, cell migration, and propidium iodide (PI) staining. The results demonstrated that TBZ- 13 significantly inhibits clonogenic survival and cell migration, while inducing pronounced nuclear condensation and fragmentation, confirming apoptosis. Moreover, TBZ-13 caused a marked increase in intracellular ROS levels, indicating that oxidative stress-mediated cytotoxicity is a leading mechanism of cytotoxicity. Results and Discussion: Notably, TBZ-13 outperformed the reference drug troglitazone in suppressing metastatic potential and promoting cancer cell death. Molecular docking studies were conducted to investigate interactions with peroxisome proliferator-activated receptor gamma (PPAR-γ), a key target implicated in tumor progression, angiogenesis, and metastasis. The crystal structure of human PPAR-γ (PDB ID: 1FM9; resolution 2.10 Å) was used for docking analysis. TBZ-13 displayed favorable binding conformations with critical hydrogen bonding interactions involving Tyr473, His323, and Ser289. Overall, these findings suggest that TBZ-13 is a promising anticancer lead candidate for further development. Conclusion: The study focuses on breast cancer, a leading cause of death globally, introducing a series of thiazolidinedione–benzimidazole hybrid derivatives (TBZ1–15) evaluated for anticancer activity against the MCF-7 cell line. TBZ-13 showcased the highest cytotoxicity with an IC₂⁽ of 35 μM. Subsequent in vitro assays revealed that TBZ-13 inhibits cell migration and clonogenic survival, induces apoptosis through nuclear condensation, and increases reactive oxygen species (ROS), indicating oxidative stress as its cytotoxic mechanism.